The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

With Casgevy’s buildup, two new drugs launching in 2025 and three others likely to complete Phase-III trials in 2026, further growth is likely over the next few years. Vertex has a market value ...

but Vertex will continue to face that risk unless it can diversify its lineup. Fortunately, it has done that in recent years. In 2023, it earned approval for Casgevy, a gene-editing treatment for ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

Vertex provided 2025 revenue guidance of $ ... along with the continued ramp of CASGEVY globally. JOURNAVX is anticipated to contribute more significantly in the second half of 2025, as payer ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

Vertex reported solid fourth-quarter numbers ... and there are several other products in late-stage development. Its Casgevy sickle-cell disease treatment continues to launch worldwide, and ...